Targets › NAGLU
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2029.
Involved in the degradation of heparan sulfate. (UniProt, P54802)
Open in Phaseline: the race on NAGLU, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| JCR Pharmaceuticals | JR-441 (posnafusp alfa) Recombinant N-acetyl-alpha-glucosaminidase (NAGLU) enzyme replacement therapy | NAGLU | Phase 1 | Mucopolysaccharidosis III-A | Oct 2029 |
Mucopolysaccharidosis III-A (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.